Clinical observation of lobaplatin combined with IL-2 thoracic perfusion in the treatment of malignant pleural effusion

Abstract

Objective To observe the clinical effect of lobaplatin combined with IL-2 in the treatment of malignant pleural effusion. Methods 42 patients with malignant pleural effusion in Datong Coal Group Co Cancer Hospital form 2014 to 2016 were enrolled as observation group, and treated with lobaplatin combined with IL-2.Another 45 patients with malignant pleural effusion in the same period were selected as control group, and treated with lobaplatin.The efficacy and toxicity between the two groups were compared.The VEGF, CEA and TSGF were recorded in the two groups.The quality of life was evaluated by QLQ-C30. Results The CR and PR rates in the observation group were 35.7% and 45.2%, respectively, which in the control group were 15.6%, 22.2%, respectively, the differences between the two groups were statistically significant (χ2=4.672, 5.178, all P 0.05). The levels of VEGF, CEA and TSGF in the observation group were (194.6±25.4)ng/L, (42.4±9)ng/L and (81.3±10.3)U/mL, respectively, which were significantly lower than those in the control group[(195.0±24.1)ng/L, (43.1±9.5)ng/L, (80.9±9.4)U/mL](t=-0.075, -0.340, 0.189, all P<0.05). The improvement of dyspnea symptoms, mood and overall health status in the observation group was better than those in the control group(t=23.326, -2.275, 10.757, all P<0.05). Conclusion Lobaplatin combined with IL-2 pleural perfusion has significantly curative effect, it can improve the quality of life and without increased toxicity in the treatment of malignant pleural effusion. Key words: Pleural effusion, malignant; Lobaplatin; Interleukin-2; Chemotherapy, cancer, regional perfusion; Quality of life; Toxic actions; Comparative effectiveness research